SCHEMBL3377129

SCHEMBL3377129

N#Cc1cccc(S(=O)(=O)N(Cc2ccc(Cl)cc2)c2ccc(F)c(C(=O)O)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
RORC P51449 1/20 0.46
CNR1 P21554 2/20 0.46
CNR2 P34972 2/20 0.46
KCNA5 P22460 2/20 0.46
NR1H2 P55055 1/20 0.46
LMNA P02545 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
PTPN22 Q9Y2R2 2/20 0.45
KCNH2 Q12809 1/20 0.45
POLB P06746 1/20 0.44
NR3C1 P04150 1/20 0.44
PKM P14618 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MCL1 Q07820 1/20 0.43
PGR P06401 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379276 0.87 NR1H2 (0.45) MEN1KMT2ARORCCNR1CNR2
SCHEMBL302783 0.87 SIRT2 (0.45) MEN1KMT2ARORCCNR1CNR2
SCHEMBL3376406 0.86 SIRT2 (0.44) MEN1KMT2ARORCCNR1CNR2
SCHEMBL3377427 0.85 KCNA5 (0.45) MEN1KMT2ARORCCNR1CNR2
SCHEMBL3380912 0.84 SIRT2 (0.45) MEN1KMT2ARORCCNR1CNR2
SCHEMBL303675 0.84 SIRT2 (0.43) MEN1KMT2ARORCCNR1CNR2
SCHEMBL303335 0.84 NR1H2 (0.45) MEN1KMT2ARORCCNR1CNR2
SCHEMBL303336 0.84 NR1H2 (0.45) MEN1KMT2ARORCCNR1CNR2
SCHEMBL2186792 0.84 SIRT2 (0.45) MEN1KMT2ARORCCNR1CNR2
SCHEMBL303674 0.83 SIRT2 (0.44) MEN1KMT2ARORCCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 MEN1 608/4885KMT2A 386/4885RORC 3865/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 MEN1 2747/4885KMT2A 1511/4885RORC 953/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 MEN1 608/4885KMT2A 386/4885RORC 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.